LDL-C level reduction <25 mg/dL with alirocumab not tied to MACE reduction: Circulation Medha29 Jan 2021 3:57 PM GMTUSA: Acute coronary syndrome (ACS) patients treated with alirocumab who achieved LDL-C levels <25 mg/dL versus 25–50 mg/d did not show any...
Semaglutide reduces major adverse CV event risk in Diabetics with raised triglycerides MD Bureau1 Jan 2021 11:45 AM GMTA posthoc analysis on SUSTAIN 6 and PIONEER 6 trial showed semaglutide was associated with consistent reduction in major Adverse cardiovascular event...
Metformin significantly lowers death risk due to cardiac and other causes: Study Medha14 Dec 2020 7:15 AM GMTItaly: Compared to other anti-hyperglycaemic drugs or placebo, the use of metfomin significantly lowers the mortality risk and MACE risk in patients...
High blood sugar levels increase CV risk in elderly diabetics: Study Medha22 July 2020 11:12 AM GMTSpain: HbA1c>7%, a measure of average blood sugar may increase the risk of major adverse cardiovascular events (MACE) in diabetes patients...
Does ticagrelor lower the risk of MACE in patients of ACS undergoing PCI? Dr. K B Aarthi7 March 2020 5:00 AM GMTOne year after PCI, patients taking ticagrelor had similar rates of MACE and faced greater safety risks.
